Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15570720 | 0.81 | ALDH1A1 (0.36) | SCN4ACYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL28728503 | 0.79 | ALDH1A1 (0.34) | SCN4ACYP1A2CYP3A4CYP2D6NFKB1 | |
| Hydrochloric Acid SCHEMBL7861505 | 0.79 | ALDH1A1 (0.34) | SCN4ACYP1A2CYP3A4CYP2D6NFKB1 | |
| Hydrochloric Acid SCHEMBL8524602 | 0.79 | ALDH1A1 (0.34) | SCN4ACYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL15569997 | 0.79 | ALDH1A1 (0.33) | SCN4ACYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL10538165 | 0.77 | ALDH1A1 (0.32) | SCN4ACYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL324572 | 0.73 | ALDH1A1 (0.39) | — | |
| SCHEMBL15570794 | 0.70 | SCN4A (0.35) | SCN4A | |
| SCHEMBL15570505 | 0.70 | — | — | |
| SCHEMBL21694740 | 0.69 | SCN4A (0.41) | SCN4ACYP1A2CYP3A4CYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2887927-B1 | EXTENDED RELEASE COMPOSITIONS OF AN AMINO-C2-C6-ALKYL NITRATE | CARDIOLYNX AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20180036259-A1 | NO DONORS FOR THE TREATMENT OF IMPAIRED TISSUE PERFUSION | MIRANDAPHARMACEUTICALS AG (CH) | 2018-02-08 | — | — | US | disclosed |
| US-20180008558-A1 | EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE | CARDIOLYNX AG (CH) | 2018-01-11 | — | — | US | disclosed |
| US-20170100350-A1 | EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE | CARDIOLYNX AG (CH) | 2017-04-13 | — | — | US | disclosed |
| WO-2016135262-A1 | NO DONORS FOR THE TREATMENT OF IMPAIRED TISSUE PERFUSION | CARDIOLYNX AG (CH) | 2016-09-01 | — | — | WO | disclosed |
| WO-2016135263-A1 | NO DONORS FOR THE TREATMENT OF STRESS-INDUCED PULMONARY HAEMORRHAGE IN ANIMALS | SCHERHAG ARMIN (CH) | 2016-09-01 | — | — | WO | disclosed |
| US-20150216992-A1 | EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE | CARDIOLYNX AG (CH) | 2015-08-06 | — | — | US | disclosed |
| EP-2887927-A1 | EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE | Cardiolynx AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014029841-A1 | EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE | CARDIOLYNX AG (CH) | 2014-02-27 | — | — | WO | disclosed |